Market Overview

UPDATE: BMO Capital Markets Reiterates Market Perform RAting, Raises PT on Scotts Miracle-Gro

Share:
Related SMG
Why Jane West's New Marijuana Product Line Might Be A Game Changer For Women
From Military Commander To Cannabis CEO: The Story Of One Of The Fastest-Growing Tech Companies In The Marijuana Industry
The State Of Marijuana Stocks And What To Look For In 2018 (Seeking Alpha)

In a report published Friday, BMO Capital Markets reiterated its Market Perform rating on Scotts Miracle-Gro (NYSE: SMG), and raised its price target from $38.00 to $40.00.

BMO Capital noted, “SMG reported 4Q of ($0.59) that was in line with estimates. Management gave its perspective on the year and noted that detail about its outlook would be provided at the December 14 analyst meeting. In broad strokes, in a best-case scenario, SMG expects to restore profitability to the FY2010 operating margin (13.5%) by the end of FY2014. It expects charges in the US to flow through the income statement, but a separate charge could be announced for the European business. Management believes that FY2013 EPS will, at the very least, reach the consensus of $2.57.”

Scotts Miracle-Gro closed on Thursday at $42.20.

Latest Ratings for SMG

DateFirmActionFromTo
Nov 2017Bank of AmericaMaintainsBuy
Nov 2017JP MorganDowngradesOverweightNeutral
Jan 2017SunTrust Robinson HumphreyDowngradesBuyHold

View More Analyst Ratings for SMG
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (SMG)

View Comments and Join the Discussion!

Partner Center